Treatment of Portal Systemic Encephalopathy: The Old and New Treatments

  • Misael Uribe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 272)


Previous chapters have discussed in deep the pathogenesis of hepatic encephalopathies. It is well recognized that portal systemic encephalopathy is a multifactorial syndrome and that, in general, in its chronic recurrent presentation or in acutely precipitated coma, the episode of encephalopathy is reversible unless the precipitating factor per se carries a high degree of mortality (i.e. massive gastrointestinal bleeding, fulminant viral infection, etc) (1).


Hepatic Encephalopathy Cirrhotic Patient Sodium Benzoate Blood Ammonia Vegetable Diet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Uribe M., Insuficiencia y coma hépatico. En Tratado de Medicina Interna. Uribe M. Editor. Editorial med. Panamericana. Chapter 184 p 1304. Mexico-Buenos Aires 1988.Google Scholar
  2. 2.
    Hoyos A., Valdovinos MA, Uribe M. Encefalopatia hepatica. Parte II. Tratamiento. Rev Gastroent Mex 1989; 54:35–40.Google Scholar
  3. 3.
    Uribe M. Dietary management of portal systemic encephalopathy. In Hepatic encephalopathy: management with lactulose and related carbohydrates. H. Conn and J. Bircher Eds. Medi Ed press. East Lansing Michigan. 1989. pp 95–112.Google Scholar
  4. 4.
    Uribe M., Guevara L., Encephalopatia hepatica. In: Berenguer J Ed. Gastroenterologia y Hepatologia, chapter 51. Barcelona Spain. Ediciones Doyma 1986, 715–723.Google Scholar
  5. 5.
    Bakti G., Fish HV., Kazlganis G et al . Mechanism of the excessive sedative response of cirrhotics to benzodiazepines. Hepatology 1987; 7:629–638.PubMedCrossRefGoogle Scholar
  6. 6.
    Marchesini G., Forlani G., Zoli M. et al .Insulin and glucagon levels in liver cirrhosis. Dig Dis Sci 1979; 24:594–601.PubMedCrossRefGoogle Scholar
  7. 7.
    Rikkers L., Jenko P. Rudman D. et al . Subclinical hepatic encephalopathy, detection, prevalence and relationship with nitrogen metabolism. Gastroenterology 1978; 75:462–469.PubMedGoogle Scholar
  8. 8.
    Uribe M. Marquez MA., Garcia Ramos G et al . Treatment of chronic portal systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study. Dig Dis Sci 1982; 27:119–126.CrossRefGoogle Scholar
  9. 9.
    Uribe M. Dibildox M., Malpica S. et al . Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. Gastroenterology 1985; 88:901–906.PubMedGoogle Scholar
  10. 10.
    Garcia Compean D., Uribe M. Fiber rather than protein determines tolerance to nitrogen load in chronic portal systemic encephalopathy. Hepatology 1987; 7:1034.Google Scholar
  11. 11.
    Max JL. Amaranthus, A comeback for the food of the Aztecs. Science 1977; 98 4312.Google Scholar
  12. 12.
    Weber FL., Minco D., Fressard KM. et al . Effects of vegetable diets on nitrogen metabolism in cirrhotic subjects. Gastroenterology 1985; 89:538–544.PubMedGoogle Scholar
  13. 13.
    Uribe M., Marquez MA., Garcia Ramos G. et al . Treatment of chronic portal systemic encephalopathy with lactose in lactase deficient patients. Dig Dis Sci 1980;; 25:924–929PubMedCrossRefGoogle Scholar
  14. 14.
    Pomare EW., Carbohydrate fermentation in the human colon and its relation to acetate concentration in venous blood. J Clin Invest 1985; 74:1448–1454.CrossRefGoogle Scholar
  15. 15.
    Jacobs LR., Lupton JR. Dietary wheat bran lowers colonic pH in rats. J Nutr 1982; 112:592–594.PubMedGoogle Scholar
  16. 16.
    Reding P., Duchateu J., Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Lancet 1984; 2:493–494.PubMedCrossRefGoogle Scholar
  17. 17.
    Uribe M., Campollo O., Vargas F., et al . Acidifying enemas vs. nonacidifying enemas to treat acute portal systemic encephalopathy: a double blind, randomized clinical trial. Hepatology 1987; 7:639–643.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossi Fanelli F., Attili A., Cascino A et al ., Vallutazione de 1a eficacia de la tollerabilita del latulossio in forma purificatta nella profilassi e nel trattamento dellencepahlopatia portosistemica. Gaz Med Ita. 1980; 139:267–270.Google Scholar
  19. 19.
    Uribe M. Toledo H., Perez F. et al . Lactitol a second generation disaccharide for treatment of chronic portal systemic encephalopathy. A double blind crossover, randomized clinical trial. Dig Dis Sci 1987; 32:1345–1353PubMedCrossRefGoogle Scholar
  20. 20.
    Uribe M. Moreno Berthier J. Lewis H et al . Lactose enemas plus placebo tablets vs neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double blind randomized controlled study. Gastroenterology 1981; 81:101–106.PubMedGoogle Scholar
  21. 21.
    Uribe M., Conn H. Effects of antacids on intestinal response and stool acidification induced by lactulose and lactose in lactose intolerant subjects. Gastroenterology 1982; 82:1248.Google Scholar
  22. 22.
    Uribe M. Management of portal systemic encephalopathy with lactose. In: Hepatic encephalopathy: Management with lactulose and related carbohydrates. H Conn and J Bircher. Medi Ed press. East Lansing Mich 1989. Chapter 20 pp 283.Google Scholar
  23. 23.
    Horst D., Grace ND., Conn HO. Comparison of dietary protein with an oral branched chain enriched aminoacid supplement in chronic portal systemic encephalopathy. Hepatology 1984; 4:279–287.PubMedCrossRefGoogle Scholar
  24. 24.
    Uribe M., Farca A., Marquez MA., Treatment of chronic portal systemic encephalopathy with bromocriptine. A double blind controlled trial. Gastroenterology 1979; 76:1347–1351PubMedGoogle Scholar
  25. 25.
    Uribe M. Garcia Ramos G., Ramos MH et al ., Standard and higher doses of bromocriptine for severe chronic portal systemic encephalopathy. Am J Gastroenterology 1983; 517–522.Google Scholar
  26. 26.
    Schafer DF., Jones EA. Hepatic encephalopathy and the gamma aminobutyric acid neurotransmitter system. Lancet 1982; 1:18–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Cooper JL., Erlich ML., Plum F. Hepatic encephalopathy: GABA or ammonia. Lancet 1984; 2:158–159.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferenci P. Grimm G., Gangl A., Successful longtime treatment of chronic hepatic encephalopathy with a benzodiazepine antagonist. Hepatology 1987; 7: 1064.Google Scholar
  29. 29.
    Van der Rijt CCD, Schalm SW., Meulstee J et al . Flumazenil therapy for hepatic encephalopathy: a double blind crossover study. Presented at the annual meeting of the AASLD abs num. 85, 1989.Google Scholar
  30. 30.
    Bathshaw ML., Brusilow S., Lewis MD. et al Treatment of inborn errors of urea synthesis. NEJM 1982; 306:1387–1392.CrossRefGoogle Scholar
  31. 31.
    Mendenhall CL., Rouster S., Marshall L, A new therapy for portal systemic encephalopathy. Am J Gastroenterology 1986; 81:540–543.Google Scholar
  32. 32.
    Uribe M. Gil., Poo JL. Bosques F. Hyperammonemic hepatic encephalopathy treated with sodium benzoate. Final report of a double blind evaluation. Presented at the annual AASLD meeting. Nov 1989.Google Scholar
  33. 33.
    O’Connor JE., Ribelles M., Grisolia S. Potentiation of hyperammonemia by sodium benzoate in animals: a note of caution. Eur J Pediatr 1982; 138:186–187.PubMedCrossRefGoogle Scholar
  34. 34.
    O’Connor JE, Costell M, Grisolia S. The potentiation of ammonia toxicity by sodium benzoate is prevented by L-carnitine. Biochem. Biophys. Res Comm 1987; 145:817–824.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Misael Uribe
    • 1
  1. 1.Instituto Nacional de la Nutricion and Clinica y Fundación Medica SurD.FMexico

Personalised recommendations